Christopher Pargellis

Author

Boehringer Ingelheim (United States)

Also Known As

C Pargellis, C. Pargellis, C.P. Pargellis, Christopher Pargellis

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (United States)Boehringer Ingelheim (Japan)Brown University Boehringer Ingelheim (Germany)Boehringer Ingelheim (France)

About

Christopher Pargellis is an author at Boehringer Ingelheim (United States) specializing in medicine, biochemistry, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	1.2K
2	Biochemistry	7	7	1.2K
3	Natural Sciences	6	6	359
4	Cell Biology	2	2	897
5	Engineering	1	1	54

Christopher Pargellis

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site Christopher Pargellis, Liang Tong, Laurie Churchill, Nature Structural Biology Molecular PharmacologyDrug TargetMolecular PhysiologySignal TransductionBiochemistry	2002	832
Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase K.A. Cohen, John Hopkins, Richard H. Ingraham, Journal of Biological Chemistry ImmunologyMolecular BiologyAntiviral DrugMedicinal ChemistryHuman Retrovirus	1991	116
Discovery and Characterization of a Substrate Selective p38α Inhibitor Walter Davidson, Lee Frego, Gregory W. Peet, Biochemistry	2004	110
Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease Daniel Lamarre, G Croteau, Elizabeth Wardrop, Antimicrobial Agents and Chemotherapy Potent InhibitorMedicineImmunologyAntiviral ResponseAnti-hiv-1 Activity	1997	74
Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. Christopher Pargellis, John R. Regan PubMed ImmunologyCell DeathP38 InhibitorsP38 Mitogen-activated ProteinOsteoporosis	2003	65
The discovery of carboline analogs as potent MAPKAP-K2 inhibitors Jiang‐Ping Wu, Ji Wang, Asitha Abeywardane, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryMedicineNatural SciencesPharmacological Agent	2007	58
Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures. Liang Tong, Susan Pav, Christopher Pargellis, Proceedings of the National Academy of Sciences Hiv-2 ProteaseCrystal StructureProtein ChemistryBiochemistryProtein Assembly	1993	58
Trichodiene biosynthesis and the stereochemistry of the enzymatic cyclization of farnesyl pyrophosphate David E. Cane, Hyun‐Joon Ha, Christopher Pargellis, Bioorganic Chemistry BiosynthesisBioorganic ChemistryTrichodiene BiosynthesisBiochemistryEngineering	1985	54
Partial purification and characterization of pentalenene synthase David E. Cane, Christopher Pargellis Archives of Biochemistry and Biophysics BiosynthesisBiochemistryNatural SciencesBiocatalysisPentalenene Synthase	1987	50
Discovery and Optimization of p38 Inhibitors via Computer-Assisted Drug Design Daniel R. Goldberg, Ming‐Hong Hao, Kevin Qian, Journal of Medicinal Chemistry	2007	24

Page 1